• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Proveris Scientific
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Phase 2 study of ISTA’s bepotastine-steroid nasal spray begins

ISTA Pharmaceuticals says that it has initiated a Phase 2 study of its Beposone bepotastine besilate/steroid combination nasal spray for the treatment of seasonal allergic rhinitis. Approximately 600 patients with allergic rhinitis caused by mountain cedar pollen are expected to take part in the randomized, placebo-controlled, parallel-group environmental study, which will be conducted in Texas. The company expects to complete the study by mid-2012.

A Phase 2 study of ISTA’s Bepomax nasal spray, a formulation of bepotastine besilate, demonstrated significantly significant improvement in nasal symptoms compared to placebo for three different combinations. The company already markets a bepotastine opthalmic formulation. ISTA licensed nasal dosage rights for bepotastine in North America from Tanabe Seiyaku in 2007 and filed an IND for Beposone in October 2011.

ISTA VP of Clinical Research and Medical Affairs Timothy R. McNamara commented, “Based upon extensive conversations with allergists to determine their prescribing habits and treatment preferences, we expanded our bepotastine besilate nasal spray program to add development of a bepotastine-steroid combination product since antihistamines and steroids are often prescribed together for treatment of seasonal allergic rhinitis.”

Read the ISTA press release.

Share

published on January 5, 2012

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Catalent banner
    © 2025 OINDPnews